Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the first part of the study (subgroup R&D) is to demonstrate the safety and performance of the C-Scan system and to collect data in order to improve the analysis process. The purpose of the second part of the study (subgroup pre-pivotal) is to determine the ability of the C-Scan System to identify elevated risk subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single arm | Experimental | All study participants will undergo the C-Scan System procedure, followed by a standard of care optical colonoscopy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| C-Scan System | Device | Subjects will be provided with contrast agent and dietary fiber pills, and instructed to start intake approximately 48 hours prior to the planned C-Scan procedure start. C-Scan system intervention includes ingestion of the C-Scan Cap and attachment of the C-Scan track to the subject's lower back. The subject is required to keep the C-Scan Track attached to the lower back and to continue intake of contrast agent and dietary fiber pills until the C-Scan Cap's natural excretion. Standard of care optical colonoscopy will be performed within 60 days from the C-Scan Cap ingestion. |
| Measure | Description | Time Frame |
|---|---|---|
| Determine the ability of the C-Scan System to identify elevated risk subjects | Sensitivity for detecting subjects with elevated risk for polyps | 60 days |
| Determine the ability of the C-Scan System to identify elevated risk subjects | Specificity for detecting subjects with elevated risk for polyps | 60 days |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of device or procedure related adverse events | Analysis of safety data | Up to 7 days post C-Scan procedure completion |
| Satisfaction with the C-Scan procedure assessed by a questionnaire |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Subject who is not a suitable candidate for a colonoscopy
Known history of dysphagia or other swallowing disorders.
Third (3rd) and fourth (4th) exclusion criteria are applicable to the pre-pivotal subgroup only:
History of the following:
GI bleeding within the last 3 months i.e., rectal outlet bleeding, hematochezia or melena
Known motility disorders:
Known IBD (Crohn's, ulcerative Colitis)
Prior history of gastrointestinal tract surgery.
Prior history of abdominal surgery that might cause bowel strictures leading to capsule retention, as determined by physician discretion.
Any condition believed to have an increased risk for capsule retention, known strictures, any prior episode of bowel obstruction: known bowel adhesion, any 'obstacles' to free passage of the capsule (such as intestinal tumors, radiation enteritis) or incomplete colonoscopies or incomplete colonoscopies as determined by physician discretion.
Significant change in diameter and frequency of stool within the last 3 months
Has an implanted cardiac device or any other implanted active device
Known sensitivity to iodine or hyperthyroidism
Acute kidney failure
Known condition which precludes compliance or is contraindicated with study and/or device instructions.
Has any procedure requiring contrast agent or which may introduce electronic interference (such as magnetic resonance imaging, DEXA scan) or an imaging procedure pre-scheduled within 14 days of C-Scan ingestion
Nuclear imaging procedure during 4 weeks before C-Scan procedure
Known condition of opioid use disorder and/or alcoholism.
Women who are either pregnant or nursing at the time of screening (to be verified by urine or serum pregnancy test for woman of child- bearing potential who are not post-menopausal or undergone surgical sterilization(
Concurrent participation in another clinical trial using any investigational drug or device.
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Hanit Brenner- Lavie, PhD | Contact | 97248303401 | hanit.brenner@check-cap.com | |
| Daniella Bleistein, MSc | Contact | 972-4-8303401 | daniella.bleistein@check-cap.com |
| Name | Affiliation | Role |
|---|---|---|
| Nadir Arber, Professor | Tel Aviv Medical Center, Israel | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Emek Medical Center | Recruiting | Afula | Israel |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 16, 2023 | |
| Reset | Mar 14, 2024 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 16, 2023 | Mar 14, 2024 |
Not provided
Not provided
Not provided
Not provided
Not provided
|
Satisfaction questionnaire to be completed by the subject
| Up to 7 days post C-Scan procedure completion |
| Satisfaction with the C-Scan procedure compared to colonoscopy assessed by a questionnaire | Satisfaction questionnaire to be completed by the subject | Up to 7 days post colonoscopy |
| Evaluate the Whole Gut Transit Time | Time elapsed from capsule ingestion to excretion | During the C-Scan procedure |
| Soroka Medical Center | Terminated | Beersheba | 3030000 | Israel |
| Bnei Zion Medical center | Recruiting | Haifa | Israel |
|
| Lin- Clalit | Recruiting | Haifa | Israel |
|
| Rambam Medical Center | Recruiting | Haifa | Israel |
|
| Talpiot- Clalit | Terminated | Jerusalem | Israel |
| Meir Medical Center | Recruiting | Kfar Saba | Israel |
|
| Galil Medical Center | Recruiting | Nahariya | Israel |
|
| Laniado Medical Center | Recruiting | Netanya | Israel |
|
| Tel Aviv Medical Center | Recruiting | Tel Aviv | Israel |
|